Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib in KRAS mutant NSCLC
NCT01951690Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Sep 2013
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib in non-small cell lung cancer (NSCLC), sponsored by Verastem Oncology. Started Sep 2013; status: completed.
02
Drugs
defactinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01951690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951690.